

Open Research Online

The Open University's repository of research publications and other research outputs

Techniques and issues in breath and clinical sample headspace analysis for disease diagnosis

Journal Item

How to cite:

Turner, Claire (2016). Techniques and issues in breath and clinical sample headspace analysis for disease diagnosis. *Bioanalysis*, 8(7) pp. 677–690.

For guidance on citations see [FAQs](#).

© 2016 Future Science



<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Version: Accepted Manuscript

Link(s) to article on publisher's website:

<http://dx.doi.org/doi:10.4155/bio.16.22>

<http://www.future-science.com/doi/full/10.4155/bio.16.22>

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online's data [policy](#) on reuse of materials please consult the policies page.

oro.open.ac.uk

Techniques and issues in breath and clinical sample headspace analysis for disease diagnosis

Claire Turner, The Open University, Walton Hall, MK7 6AA

Abstract

Analysis of volatile organic compounds (VOCs) from breath or clinical samples for disease diagnosis is an attractive proposition because it is non-invasive and rapid. There are numerous studies showing its potential, yet there are barriers to its development. Sampling and sample handling is difficult, and when coupled with a variety of analytical instrumentation, the same samples can give different results. Background air and the environment a person has been exposed to can greatly affect the VOCs emitted by the body, however this is not an easy problem to solve. This review investigates the use of VOCs in disease diagnosis, the analytical techniques employed and the problems associated with sample handling and standardization. It then suggests the barriers to future development.

Keywords

VOCs, breath analysis, biomarkers, SIFT-MS, GC-MS, headspace analysis, disease diagnosis, PTR-MS, e-nose, spectroscopy,

Executive summary

Introduction

- It has been known for centuries that some diseases have an odour associated with them
- Modern volatile organic compound (VOC) analysis for disease diagnosis has arisen from this

The origin of VOCs

- VOCs arise from normal or abnormal metabolic processes in the body and from the bacteria that live in or on the body
- Some illnesses results in a difference of the profile of VOCs emitted in breath or from other body fluids
- Infectious disease may also produce a change in the profile of VOCs.
- VOCs also arise from the body through exposure to them in the environment

33 *Sampling and handling considerations*

- 34 • A major difficulty in using VOCs in diagnosing or detecting disease is being able to
35 handle and store them
- 36 • Whole breath may be analysed directly if it is possible to get the patient to the
37 instrument
- 38 • If it is not possible to do this, samples need to be stored
- 39 • Whole breath can be stored in sample bags or evacuated metal canisters
- 40 • If whole breath cannot be stored, sorbent methods such as SPME (solid phase micro-
41 extraction) or the use of sorbent tubes can be coupled with analytical techniques
42 such as gas chromatography mass-spectrometry
- 43 • These indirect methods are sensitive but not all compounds may be detected and
44 quantified.

45 *Techniques*

- 46 • Trace gas analysis mass spectrometric techniques offer rapid and direct analysis but
47 are often cumbersome and expensive
- 48 • Laser based spectroscopic techniques are rapid and direct and may be used instead
49 of mass spectrometry for some compounds
- 50 • Non-specific sensors may be assembled into an array called an electronic nose,
51 which respond to different odours by producing a complex signal. E-noses are rapid,
52 portable and relatively inexpensive but cannot identify individual compounds.
- 53 • The most widely used technique is a combination of gas chromatography (GC) and
54 mass spectrometry (MS). Sample components are separated by GC and then
55 identified by MS. This is a powerful technique, but it is slow, cumbersome and
56 expensive.

57 *Backgrounds*

- 58 • The environment to which a subject has been exposed will contribute its own VOCs,
59 and these will be exhaled or excreted by the body for some time after, depending on
60 their retention co-efficient in the body.
- 61 • There needs to be some way of accounting for the variation in background
62 environments to which subjects are exposed.
- 63 • There is no perfect way of accounting for background air, but several methods have
64 been tried, for example by analyzing the background and subtracting those VOC
65 concentrations, calculating retention co-efficients for compounds of interest, or
66 selecting matched controls who have lived in a similar environment.

67 *Standardisation*

- There are no acknowledged standardized ways of taking, handling, storing and analyzing breath and clinical fluid samples for VOC analysis
- As there are many different methods for taking and analyzing samples, standardization methods need to focus on ensuring that each method should give the same results when analyzing identical samples.
- This can be achieved through using standardised artificial breath test mixtures and validating methods against these.

Future perspective

- VOC analysis for disease diagnosis is promising but progress is slow
- Standardization is necessary
- Profiles from multiple compounds is likely to be more robust at diagnosis than the use of individual marker compounds
- Properly validated statistical methods are needed to ensure findings are robust and repeatable
- This approach has great potential but further work is needed to ensure it is at least as robust and accurate as existing diagnostic techniques

Key references

*References of considerable interest ***

[10], [43]. These articles are of particular interest as they summarise the knowledge available of the range of VOCs that are generated from various body fluids

[128] This article explains the need for standardization in breath sampling.

[112] This shows the huge range of VOCs which may be analysed as instruments have improving sensitivity, however with complex data sets, use of this information is harder.

*References of interest **

These articles are of interest because they give examples of where VOC analysis can be used in diagnosis: [15], [40].

[125] is important because it gives an effective method for dealing with background air, although only for known compounds.

Introduction

The ancient Greeks were known to use the odour of volatile organic compounds emitted from breath and body fluids as an aid to diagnosis [1], but it wasn't until Linus Pauling and

co-workers [2] condensed human breath and analysed its constituents using gas chromatography that modern breath analysis began. Linus Pauling was also involved in the early analysis of volatile organic compounds (VOCs) from urine in the 1970s [3,4]. It was still another decade or two before it really took off, but since the mid 1990s, there has been a very rapid development of analytical instrumentation to enable breath analysis to expand [5-8]. In actual fact, VOCs and other trace gases such as ammonia and hydrogen cyanide (which for the purposes of this article are included when VOCs are mentioned) are emitted from all body fluids and tissues, for example breath, urine, faeces, skin, sputum, blood, serum, pus, aspirates, tissue, lavage etc. Selecting the appropriate medium for analysis is important and the choice depends on a number of factors. These include the particular disease or condition, ease of sampling, whether samples can be analysed directly or must be stored, the requirement for measuring individual compounds or a whole range, to name but a few. It is also likely that analysis of more than one sample type yields better results than just looking at breath, for example [9]

The origin of VOCs

A whole range of trace gases and volatile organic compounds are emitted by the body continuously, through exhalation, through skin or from urine or faeces. There are several potential origins of these compounds. Firstly, many VOCs arise from normal metabolism. The body contains thousands of different molecules arising from all the biochemical pathways, and many of these compounds are either gases (for example ammonia) or are volatile enough to form a vapour at body temperature. These compounds travel around the body in blood, and where blood meets the alveoli in the lungs, rapid gas exchange and diffusion means that gases and VOCs are exhaled. Similarly, when capillaries are in contact with skin, gas exchange occurs. VOCs are also excreted as part of the chemical composition of urine or faeces. Thus it can be seen that through normal metabolism, the healthy body produces a whole range of different compounds at different concentrations [10].

When illness occurs, metabolism can alter the profile of trace gases and VOCs [11,12]. For example, untreated diabetes leads to a build-up of blood glucose which cannot enter the cells where it is needed. In response, the body starts to metabolise fat, which then leads to an increase in ketone bodies in blood [13]. Some of these are very volatile, and may be detected on breath, in blood or urine. So it is clear that different profiles of metabolites (including volatile metabolites) occur through illness. Cancer is another condition where the VOC profile may change. This may be because various metabolic pathways are expressed to a greater or lesser extent in a cancer cell compared with a normal cell. In addition, the pH of the cell and its surrounding medium may change, thus rendering the relative acid/base equilibria of various compounds change hence various volatile species may increase or decrease merely as a result of pH. So you would expect to see more organic acids in the volatile form when the pH is lower, for example with acetic acid, CH_3COOH , and its

equilibrium with the acetate ion, CH_3COO^- would be shifted to have more of the CH_3COOH species, which is volatile, while CH_3COO^- is not. Conversely, at a lower pH, the concentration of ammonia as NH_3 would be lower than NH_4^+ , for example. There have been numerous studies describing differences in VOC profile in cancer [14] e.g. colo rectal cancer [15-18], lung cancer [19-22], breast cancer [23,24] other cancers [25-29].

VOCs may also be produced as a result of infection. Bacteria, fungi and parasites all have their own metabolism and thus their own profile of VOCs and trace gases. When they infect the body, it is thus reasonable to expect that the VOC profile will change with the degree of infection [30]. In addition, the response of the body (host response) in fighting the infection may also change the volatile metabolites produced [31]. In addition, the host's own metabolism may alter the chemical profile produced by the bacteria. Infection in this case also includes the colonisation of the gastrointestinal tract (and other body cavities and surfaces) by trillions of bacteria which have a major impact on the VOC profile [32]

These bacteria are generally benign, and many are even beneficial, but they produce many of the VOCs and trace gases that may be detected on breath, from skin, or from the headspace of blood, urine and faeces.

Examples of infections causing a change in VOC profile are tuberculosis [33], mycobacteria infection [31], infections causing ventilator associated pneumonia [34], respiratory disease [35]. Gastrointestinal disease may be due to a change in the gut flora, or some pathology of the gut or a combination of both, and these have been shown to give distinct VOC profiles from headspace of urine or faeces as well as breath [36-40] [41].

Finally, VOCs arise in the environment. They are produced by plants, food, man-made products or processes (diesel exhausts for example) and if inhaled or ingested, they will then circulate in the blood [42]. In the case of environmental origin of VOCs on breath, there is no simple way of dealing with this so that the background air can be excluded in analysis. This is discussed in more detail later.

A major review of all the volatile compounds emanating from the body has recently been produced, and this covers all sources of VOCs described above [43].

Sampling and handling considerations

Capturing, handling and storing VOCs and trace gases is a major challenge [44]. Unless analysed directly, e.g. using an instrument that can analyse breath in real time [45], the VOCs and gases need to be captured, concentrated and then stored. Ideally, storage should be at a very low temperature to reduce the loss of the VOCs, and the samples should be stored as soon after being taken as possible. In the case of liquid or solid samples (e.g. urine, blood, faeces, pus, aspirates etc.), this is fairly straightforward. Samples should

immediately be placed in an appropriate container and frozen, preferably to -80°C or lower. The container should be clean, and should produce no VOCs which could interfere with analysis, and obviously should not change its characteristics with the temperature change and storage. It is known that freezing samples can change their VOC composition [46], but unless every sample can be analysed immediately in the same way, all samples should be frozen immediately.

When breath is to be sampled but cannot be analysed immediately, it is necessary to store it. It can either be stored as whole breath, or if the VOCs are extracted, it can be condensed and stored. If whole breath is stored, there are a number of issues to consider. These include cost, integrity, storage time and simplicity, and also which part of the breath is sampled. Generally, it is desirable to avoid measuring the dead-space of air in the upper respiratory tract and concentrate on end tidal breath. These issues are described in detail in [44]. Probably the simplest and cheapest way of storing whole breath is in breath bags. These can be made of a variety of materials, and range from a few cents/pennies etc. for Nalophan, to the much more expensive Tedlar bags. Other materials such as Kynar and Flexfilm [47], polyvinyl fluoride and polyester aluminium [48] have also been used. Because of the cost, Nalophan is disposable, but as Tedlar is much more expensive, most people try and re-use Tedlar bags, which means a very thorough cleaning regime is required. However, it is difficult to remove all traces of previous samples, even with this. In addition, Tedlar produces a number of VOCs of its own which may contaminate the samples. Despite this, Tedlar is often the sample bag of choice because generally, samples may be stored in Tedlar for longer than in Nalophan or other sample bag materials, as Nalophan tends to be slightly porous so diffusive losses occur. Adsorption onto the walls of the bag also occurs [49]. So if samples cannot be analysed within a few hours, then Tedlar may be better [50]. There have been many studies looking at the relative merits of these sampling bags [47-49,51,52] and the choice of bag will come down to budget, analytes of interest and necessary storage time.

A more expensive option is the use of evacuated metal canisters which have been used in environmental exposure breath analysis [53-55]. Because these are expensive and difficult to clean, they are no longer used much in breath analysis.

If it is not possible or desirable to store whole breath, a sorbent material may be used which extracts the VOCs from the whole breath. There are several sorbent materials that may be used, and this can either be within a thermal desorption (TD) or sorbent tube, or using a technique such as solid phase microextraction (SPME) [56-60] or needle trap device [61]. SPME involves using a very small microfiber and inserting it into the headspace for a fixed amount of time to absorb the VOCs. Although very sensitive, it generally adsorbs some compounds preferentially over others, and as soon as removed from the headspace, may start to desorb the samples. It is also not particularly robust, and great care must be applied in handling the fibre. It is also not quantitative unless very specific steps are taken where

standards are used and the marker compounds are known; the relative concentrations of other compounds present should also be known as they will affect binding. However, SPME may be used to trap very low concentration compounds. Generally the use of TD tubes is more robust, and once samples are collected, the TD tubes may be capped and stored for weeks prior to analysis. TD tubes are also more sensitive [62] and again, accurate quantification is difficult, although slightly easier than with SPME. Great care must be taken in choosing the sorbent, and in many cases, dual or even triple bed sorbents are used in the same tube to capture the range of compounds. Some sorbents are better at lower molecular weight compounds, some higher molecular weight, and others may be better for aromatic or sulphide compounds, for example. From this it follows that to make best use of this technology, some idea of the types of compound expected is needed. Examples of where sorbent tubes techniques have been used to sample breath are in a study of patients with impaired respiratory function [63], or in a study for collecting breath from frail patients [64].

These sorbent techniques are very sensitive, and when coupled with GC-MS, compounds may be desorbed from the sorbent material (usually by heating), and then separated by gas chromatography (GC), followed by identification and quantification by mass spectrometry (MS). The advantages of doing this are that it is very sensitive, compound identification is possible through separation and mass detection, and samples may readily be collected, concentrated and stored. However, it is slow, indirect requiring several steps, and not always quantitative unless great care has been taken with sorbents and VOC amounts.

A summary of breath sampling techniques may be found in table 1.

Table 1. Summary of exhaled breath sampling techniques giving their main advantages and disadvantages

Technique	Main Advantage(s)	Main Disadvantage(s)	Reference
Direct analysis	Direct so no loss of sample integrity	Need to get equipment to patient	45
Sample bags	Diffusive losses; short storage times	Cheap and simple	47-52
Evacuated metal canisters	Re-useable; longer storage possible	Expensive; difficult to clean	53-55
Thermal desorption	Sensitive; long sample storage times	Choice of sorbent crucial; not all compounds adsorbed; quantification difficult	62-64
SPME	Very sensitive	Fragile; quantification very difficult	56-60

241 **Techniques**

242 There is a very wide range of techniques for the analysis for individual VOCs or VOC profiles
243 from a sample. These range from sophisticated and expensive techniques that can analyse
244 samples of breath or headspace directly in real time, such as selected ion flow tube mass
245 spectrometry (SIFT-MS) [65-80] or proton transfer mass spectrometry (PTR-MS) [67,81-85],
246 to techniques which do not identify or analyse individual components but look at patterns,
247 for example gas sensor arrays (electronic nose) [35,86-93]. If compound identification is
248 required, it is essential to use a mass spectrometric technique, and preferably one that is
249 coupled with a separation technique to avoid complicated spectra, for example gas-
250 chromatography-mass spectrometry.

251 Direct analysis is difficult but can be done with SIFT-MS [65-68,75,80] and PTR-MS [67,81-
252 84]. Direct analysis using these mass spectrometric methods does not allow absolute
253 identification, because compounds in samples are not separated (unlike in GC-MS, where
254 retention index as well as ions generated aids identification), and the soft chemical
255 ionisation may yield a number of ions which may arise from more than one compound.
256 Despite this, the direct methodology offers the opportunity for quantification where
257 compounds are identified, particularly with SIFT-MS [76,94]. It is a little more complicated
258 with PTR-MS, with the variation in E/N (field strength in the drift tube) but quantification is
259 in some cases possible particularly for low molecular mass compounds, and certainly with
260 the use of calibration gases for specific compounds. In SIFT-MS and PTR-MS, the sample is
261 presented to the instrument, and then reacted with a precursor ion. For SIFT-MS, a choice
262 of H_3O^+ , NO^+ or O_2^+ is possible; PTR-MS generally uses hydronium ions, H_3O^+ , but newer
263 instruments enable the use of other precursor ions. Ions are generated according to their
264 reactions with the precursors and then these product ions may then be separated by a mass
265 spectrometer, typically a quadrupole for SIFT-MS, and quadrupole or time-of-flight, TOF, for
266 PTR-MS. Whole spectra may be looked at if one is interested in looking for the range of
267 compounds present in either breath or headspace. Alternatively the instrument could be
268 set up to look for one or more specific compounds without scanning the whole spectrum,
269 which would enable more accurate quantification.

270 Laser based spectroscopic techniques have also been used for real time direct analysis of
271 breath laser based techniques [95-99] and may offer a replacement for mass spectrometric
272 techniques in the future. Similarly, ion mobility spectrometry (IMS) has also been used in
273 real time analysis of breath [20,100,101]. It is relatively low cost, however it cannot identify
274 individual compounds with certainty, although it could indicate the potential identity of
275 species based on how the sample components behave in the electric field. It has also been
276 used by the military in personal equipment for detecting the deployment of chemical
277 weapons [102].

278 Other gas sensor techniques may also be used in direct analysis of breath or headspace, but
279 these tend to be non-specific. This includes various types of so-called electronic nose, which

use an array of sensors of various types [35,86-93]. Originally, electronic noses contained between 10 and 40 sensors, but newer technology means that a very high number of sensors can be included in a small array. These sensors respond differently to the various components in a sample, and a complex array of signals is generated. By comparing signals from different classes of samples (e.g. breath samples from those with a particular illness and those without), patterns emerge which may enable differences associated with the disease to be identified. There are problems with some sensors in e-nose devices – drift over time, fouling and memory effects [103]. An increasing number of sensor elements or spectral data means increasing complexity in multivariate statistical methods to interrogate and process the data, but such techniques are also developing [15,36,37,104-108].

Further developments in sensors means that some relatively low cost sensors are becoming increasingly sophisticated, and they can be made more sensitive and also selective. Long period grating optical fibre sensors may be produced now, which are specific for individual components [109-112]. These can be assembled into an array to produce a low cost alternative to mass spectrometry, although in using a limited number of specific sensor elements means the need to know exactly which compounds should be measured and cannot be used for volatile biomarker discovery. These sensors also enable on-line analysis and could conceivably be used in a point of care device, or even personal breath analysis tool, for instance like one that can monitor asthma and nitric oxide [113].

The most widely used technique for off-line or indirect analysis of samples is probably gas chromatography-mass spectrometry (GC-MS) [11,34,36,59,114-122]. Although this technique is relatively slow and indirect, it is also very powerful. If samples are concentrated, for example by using a sorbent such as a thermal desorption tube or a SPME fibre, desorption of this can then deposit the concentrated sample onto a chromatographic capillary column. This can then separate sample components, which may then be detected sequentially according to chemical and physical properties (e.g. size, volatility and hydrophobicity). A further development in this area is the use of GCxGC MS, which deals with the problem of co-elution of compounds, where it is difficult to identify species. This is a very sensitive technique that can detect many more compounds in any sample [114,123], but it is expensive and generates much more complex spectra

Apart from being able to detect components present in the parts-per-trillion-by volume range (pptv), GC-MS is the best technique for identifying the individual components of a sample. It is quantitative if standards are run for individual compounds, but it is difficult to make it quantitative for compounds during biomarker discovery due to the complexity of the sample and the absorption/desorption differences on the sorbent between individual components.

Choosing the most suitable technique

So which technique should be used? This obviously comes down to a question of availability/budget, but generally if biomarker discovery is desired, then a mass spectrometric technique with a compound separation method, such as GC-MS, is best. However if the aim is to be able to distinguish between volatile profiles from a sample, a technique which can use multiple variables, for instance m/z or sensor array responses to produce a profile of the sample, composed of multiple compounds, then any technique may be used, coupled with suitable multivariate statistical approach. However, even if a diagnostic profile is found and is robust enough for clinical use, knowledge of the major compounds contributing to the differences in profile is highly desirable. This means that use of mass spectrometric methods in the discovery stage is ideal, and then when the compounds responsible for the change in disease state are known, then point of care devices which are less expensive and more portable are better. In the discovery stage, the use of multiple techniques which exploits the advantages of each will give the best results. For instance, the ability to directly analyse a sample and obtain quantitative data (e.g. with SIFT-MS or PTR-MS) can be used in conjunction with GC-MS which is more sensitive and is better at compound identification but is slower and not so directly quantitative.

The choice will also depend on whether the sample must be analysed directly, or whether samples may be taken and stored for subsequent analysis.

For the analysis of a small number of individual compounds, then any technique capable of being sufficiently selective is acceptable. This includes a variety of gas sensors, optic fibre sensors, IMS, mass spectrometry etc. A summary of the main techniques is given in table 2.

Table 2. Summary of analysis techniques giving their main advantages and disadvantages

Technique	Main Advantage(s)	Main Disadvantage(s)	Reference
Direct trace gas mass spectrometry	Direct, rapid	Expensive, not always easy to take to the patient	65-84, 94
Gas sensors (e-nose)	Direct, rapid, inexpensive	Non-specific; cannot identify compounds	35, 86-93, 103
Laser based spectroscopic techniques	Direct, rapid	Relatively expensive	95-99
Ion mobility spectrometry	Rapid; relatively inexpensive	Cannot identify unknown compounds	20, 100-101
Long period grating optic fibre sensors	Can be made specific & low cost; rapid	Not for biomarker discovery	109-112
GC-MS (with TD or SPME)	Sensitive; good for compound identification	Expensive, slow	11, 34, 36, 59, 114-123

340

341 **Backgrounds**

342 Something that breath analysis researchers in particular have been concerned about for
343 some time is the background air and its effect on the components of breath. It is well known
344 that inhaling compounds from the environment means that these compounds are exhaled
345 for some time after. How long the compounds will be exhaled for depends on factors such
346 as the concentration of the compound inhaled and the duration of exposure, the chemical
347 and physical nature of the compound – its molecular mass, volatility, how fat soluble it is
348 etc.; the body mass index of the individual. Because there are so many variables, it is very
349 difficult to adequately deal with this problem. Different groups have various ways of dealing
350 with this. For instance, Michael Phillips [124-126] uses the concept of alveolar gradient
351 which involves measuring the background air and looking at the difference between the
352 concentrations of various species in the air and in the breath. Although this helps in some
353 way, it is not accurate for all VOCs [127]. Other researchers insist that subjects giving breath
354 samples inhale clean air for a minimum period prior to providing a breath sample, but this
355 cannot reduce the levels of all exogenous compounds in breath. This is much less effective
356 for hydrophobic compounds and where patients have a high BMI, or where the
357 concentration of the compound is high. Schubert et al [128] has shown that the approach of
358 applying a simple background subtraction, where the concentration of the species in
359 background is subtracted from that in breath, is not effective, and substances where
360 concentrations in inspired breath is higher than 5% of expired concentrations should not be
361 used as breath markers. The best, but complicated option, is to apply retention coefficients
362 for individual compounds in the background air [127]. This requires knowledge of the
363 presence of such biomarkers and their retention coefficients. None of these are entirely
364 satisfactory because of the complexity of the problem, and people may have been exposed
365 to a number of different backgrounds with different concentrations of compound in inspired
366 air that may affect the breath prior to a breath sample being given.

367 Rather than finding a way of dealing with the background directly, an alternative may be the
368 use of appropriate controls. At the same time that a sample is taken from a patient or
369 subject, a sample should be taken from a control person who has been subjected to similar
370 backgrounds, and is as closely as possible be matched to the subject. This could be the
371 partner of the individual, for example. Other studies have used medical personnel for this
372 purpose, but that is less satisfactory as medical facilities typically have high background
373 levels of VOCs, and thus medical personnel may have been subjected to these backgrounds
374 to a greater extent than subjects. It is clear that this is a difficult problem, and backgrounds
375 should always be carefully taken into account when a breath analysis study is conducted.
376 This is also likely to have an impact on blood and urine VOCs as the origin of exogenous
377 VOCs from the headspace of these fluids may also be inhaled air. Table 3 summarises the
378 techniques for dealing with background air.

Table 3. Summary of techniques for dealing with background air, giving their main advantages and disadvantages

Technique	Main Advantage(s)	Main Disadvantage(s)	Reference
Alveolar gradient	Requires simple measurement of background air	Not accurate for many compounds	124-127
Inhaling clean air	Easy to do; requires no further measurements	Ineffective for many compounds	128
Retention coefficients	Effective	Complicated and only useful for known compounds	127
Use of appropriate controls	Will cope with problem of variable retention coefficients	Not easy to recruit appropriate controls; doubles analysis required	

Standardisation

Analysis of breath and the headspace of body fluids has been a growing field of endeavour since the 1970s, and as previously discussed, there are many techniques used. However, results from these investigations often do not correlate with each other, and one reason for this is that there is no accepted standard for sampling and analysis. To make progress in the area of VOC analysis for disease diagnosis, the importance of standardising methods for sampling and analysis of breath is being recognised [129-132]. What has not been noted is the requirement for standardisation of all samples for VOC analysis, but this is equally important.

Breath analysis

There are several aspects to this. The first is where is the sample taken from? Should it be the mouth, or nose or a combination of both? The mouth contains its own flora which produce VOCs, so measuring from the mouth alone will mean that these will change the sample [133-136]. In some cases, mouth VOCs are important, but if systemic VOCs are important, e.g. where a condition at a distant site is to be monitored, then avoiding the contamination from mouth flora is important. This is the case with monitoring HCN in the lungs from *Pseudomonas aeruginosa* in cystic fibrosis patients [137]. Sometimes, the origin of specific VOCs is sought, in which case, both should be analysed in turn [138].

Secondly, which part of the breath should be taken? Should it be whole breath, end-tidal breath? The answer to this depends on the degree of accuracy and precision required. Most methods for analysing VOCs in breath cannot do the analysis with any great accuracy and precision. Repeat samples, even of direct breath, often differ, depending on the compound being analysed and the background [139,140]; factors such as rate and volume of exhalation may also have an effect [141]. The variation between the concentration of VOCs

in whole breath and end tidal may not be close to this, so how important is it that methods require the complexity of a mechanism for excluding dead-space in the respiratory system and consider only end tidal breath? This would depend on the necessary precision for the analysis of a compound. If it is a compound where the presence or absence is important, this matters less, however if small variations in concentration show clinically relevant information, then the additional precision may be important.

Methods for ensuring only end-tidal breath is taken involve switching mechanisms which may check CO₂ composition of breath and then use a valve system to divert the required part of breath, discarding the dead space [34,142]. These methods are more complicated but can ensure that only a specific part of the breath is taken. However, one study [143] shows comparatively low relative standard deviation between successive bag fills of whole breath, so perhaps accepting whole breath, with apparently better reproducibility but less emphasis on control, is an acceptable option.

Aside from standardising which part of breath is taken, there are other factors that will affect the measurement. This includes the mechanism and material that transports the breath to the analytical instrument. Even if it is direct analysis, breath will start to condense on any surface which is cool enough, so the pipes/tubing/sampling port should be at a standardised (warm) temperature. The material used should also minimise “sticking” of compounds. Some molecules, for example ammonia, are very “sticky” [144] so the longer the tube/pipe etc., the more the compound will stick and thus not be available for analysis. This can also contaminate later samples.

For breath samples that are taken and then stored for subsequent analysis, further standardisation is required. It is not reasonable to expect that every researcher will use exactly the same sampling mask or mouthpiece; instead a way of checking that each method delivers the same results is required. One way of doing this is to use standardised artificial breath. This could involve special calibration vapours which are humid, as is breath, but which deliver known amounts of each analyte at a given temperature; 37°C is best as this is that of breath. Calibration standards can be purchased or standard artificial headspaces or breath can be produced by making aqueous solutions of breath VOCs, putting them in an enclosed sample bag and allowing the aqueous solution and the headspace above it to reach equilibrium. According to Henry’s law, a given concentration in the aqueous phase will be in equilibrium with the headspace above it at a given temperature. Knowing the Henry’s law coefficient for each compound of interest, these artificial headspaces can easily be generated, which will deliver standard concentrations of compounds in a headspace. These artificial breath samples or headspaces can then be presented to analytical devices and the responses assessed against each other.

Headspace of body fluids

Generating headspace of body fluids can also yield very different results depending upon how they are treated. In some cases, samples can be analysed immediately; they will need to be put in a suitable receptacle, clean gas/air added and a headspace equilibrium allowed to develop. However, generally samples of urine, blood, pus, faeces etc. are collected from a hospital or clinic and cannot be processed immediately, but will quickly degrade if not stored appropriately. In this case, standardised samples treatment and storage protocols should be developed and followed. Freezing samples at -80°C as soon as they are taken will reduce loss of VOCs, however samples can degrade under these conditions [46]. Hence standardised protocols should be developed for the sample type, duration of storage, temperature of storage and storage container. In addition, the protocol for defrosting and preparing the sample for subsequent analysis should also be standardised.

Standardisation of sample treatment, storage and use of calibration standards will enable a comparison between studies which should enable this field to be driven further. One of the main issues in the field of VOC analysis for disease diagnosis is that studies do not always give the same results; the lack of standardised protocols means that these different studies are essentially measuring different things.

Future perspective

There is an increasing number of studies on the use of VOCs in diagnosing disease, and there are now very many examples of how VOCs can be used to detect various cancers, infections, metabolic conditions, gastro-intestinal disease etc. Despite this, there are very few of these tests that are used routinely in the clinic. Given the potential advantages of VOC profiling for disease diagnosis i.e. that it is non-invasive or minimally invasive, rapid, potentially cost-effective, etc., why have these apparent diagnostic successes not translated to routine clinical analysis? There are likely to be several reasons for this. One is that mentioned above, i.e. there is no single standardised method for breath or clinical fluid headspace sampling and analysis. Another possible reason is that in some cases, there is no real attempt to get clinical buy-in for the method. Clinicians are responsible for the well-being of their patients so would need to be convinced of the effectiveness of a new test. One reason why they haven't been convinced is because studies often only involve clinicians in sample collection and not in the development the technique itself. Secondly, the output of a breath or headspace analysis may be a complex profile which needs interpreting using multivariate statistics rather than with unique individual breath biomarkers. Although the complex profiles may be fully statistically validated, they are often hard to explain, and thus effort and care needs to be taken in communicating their use. In addition, in order for a method to replace an existing screening or diagnostic method, it needs to be at least as good as the method it is replacing in every respect, and superior in at least one respect. Most studies published do not address this but it is essential for progression of this field.

However, with the vast increase in published studies showing the use of VOC profiling, surely this is only a matter of time.

References

1. West JB. History of Respiratory Gas Exchange. *Comprehensive Physiology*, 1(3), 1509-1523, (2011).
2. Teranish.R, Robinson AB, Cary P, Mon TR, Pauling L. GAS-CHROMATOGRAPHY OF VOLATILES FROM BREATH AND URINE. *Analytical Chemistry*, 44(1), 18-&, (1972).
3. Matsumot.Ke, Partridg.Dh, Robinson AB *et al.* IDENTIFICATION OF VOLATILE COMPOUNDS IN HUMAN URINE. *Journal of Chromatography*, 85(1), 31-34, (1973).
4. Pauling L, Robinson AB, Teranish.R, Cary P. QUANTITATIVE ANALYSIS OF URINE VAPOR AND BREATH BY GAS-LIQUID PARTITION CHROMATOGRAPHY. *Proceedings of the National Academy of Sciences of the United States of America*, 68(10), 2374-&, (1971).
5. Risby TH, Solga SF. Current status of clinical breath analysis. *Applied Physics B-Lasers and Optics*, 85(2-3), 421-426, (2006).
6. Cao WQ, Duan YX. Current status of methods and techniques for breath analysis. *Critical Reviews in Analytical Chemistry*, 37(1), 3-13, (2007).
7. Miekisch W, Schubert JK. From highly sophisticated analytical techniques to life-saving diagnostics: Technical developments in breath analysis. *Trac-Trends in Analytical Chemistry*, 25(7), 665-673, (2006).
8. Smith T. Breath analysis: clinical research to the end-user market. *Journal of Breath Research*, 5(3), 032001, (2011).
9. Broza YY, Zuri L, Haick H. Combined Volatolomics for Monitoring of Human Body Chemistry. *Scientific Reports*, 4, 4611, (2014).
10. Amann A, Costello B, Miekisch W *et al.* The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva. *Journal of Breath Research*, 8(3), 034001, (2014).
11. Kataoka H, Saito K, Kato H, Masuda K. Noninvasive analysis of volatile biomarkers in human emanations for health and early disease diagnosis. *Bioanalysis*, 5(11), 1443-1459, (2013).
12. Boots AW, van Berkel J, Dallinga JW, Smolinska A, Wouters EF, van Schooten FJ. The versatile use of exhaled volatile organic compounds in human health and disease. *Journal of Breath Research*, 6(2), 027108, (2012).
13. Kalapos MP. On the mammalian acetone metabolism: from chemistry to clinical implications. *Biochimica Et Biophysica Acta-General Subjects*, 1621(2), 122-139, (2003).
14. Queralto N, Berliner AN, Goldsmith B, Martino R, Rhodes P, Lim SH. Detecting cancer by breath volatile organic compound analysis: a review of array-based sensors. *Journal of Breath Research*, 8(2), 027112, (2014).
15. Batty CA, Cauchi M, Lourenco C, Hunter JO, Turner C. Use of the Analysis of the Volatile Faecal Metabolome in Screening for Colorectal Cancer. *Plos One*, 10(6), e0130301, (2015).
16. Malagu C, Fabbri B, Gherardi S *et al.* Chemoresistive Gas Sensors for the Detection of Colorectal Cancer Biomarkers. *Sensors*, 14(10), 18982-18992, (2014).
17. Arasaradnam RP, McFarlane MJ, Ryan-Fisher C *et al.* Detection of Colorectal Cancer (CRC) by Urinary Volatile Organic Compound Analysis. *Plos One*, 9(9), e108750, (2014).
18. Altomare DF, Di Lena M, Porcelli F *et al.* Exhaled volatile organic compounds identify patients with colorectal cancer. *British Journal of Surgery*, 100(1), 144-151, (2013).
19. Ma W, Gao P, Fan J, Hashi Y, Chen ZL. Determination of breath gas composition of lung cancer patients using gas chromatography/mass spectrometry with monolithic material sorptive extraction. *Biomedical Chromatography*, 29(6), 961-965, (2015).

- 530 20. Handa H, Usuba A, Maddula S, Baumbach JI, Mineshita M, Miyazawa T. Exhaled Breath
531 Analysis for Lung Cancer Detection Using Ion Mobility Spectrometry. *Plos One*, 9(12),
532 e114555, (2014).
- 533 21. de Castro MDL, Fernandez-Peralbo MA. Analytical methods based on exhaled breath for
534 early detection of lung cancer. *Trac-Trends in Analytical Chemistry*, 38, 13-20, (2012).
- 535 22. Jareno J, Munoz MA, Maldonado JA *et al.* Volatile Organic Compounds (VOC) in exhaled
536 breath in patients with lung cancer (LC). *Lung Cancer*, 77, S31-S32, (2012).
- 537 23. Li J, Peng YL, Liu Y *et al.* Investigation of potential breath biomarkers for the early diagnosis
538 of breast cancer using gas chromatography-mass spectrometry. *Clinica Chimica Acta*, 436,
539 59-67, (2014).
- 540 24. Phillips M, Beatty JD, Cataneo RN *et al.* Rapid Point-Of-Care Breath Test for Biomarkers of
541 Breast Cancer and Abnormal Mammograms. *Plos One*, 9(3), e90226, (2014).
- 542 25. Navaneethan U, Parsi MA, Lourdasamy D *et al.* Volatile Organic Compounds in Urine for
543 Noninvasive Diagnosis of Malignant Biliary Strictures: A Pilot Study. *Digestive Diseases and*
544 *Sciences*, 60(7), 2150-2157, (2015).
- 545 26. Leunis N, Boumans ML, Kremer B *et al.* Application of an Electronic Nose in the Diagnosis of
546 Head and Neck Cancer. *Laryngoscope*, 124(6), 1377-1381, (2014).
- 547 27. Abaffy T, Moller MG, Riemer DD, Milikowski C, DeFazio RA. Comparative analysis of volatile
548 metabolomics signals from melanoma and benign skin: a pilot study. *Metabolomics*, 9(5),
549 998-1008, (2013).
- 550 28. Kumar S, Huang JZ, Abbassi-Ghadi N, Spanel P, Smith D, Hanna GB. Selected Ion Flow Tube
551 Mass Spectrometry Analysis of Exhaled Breath for Volatile Organic Compound Profiling of
552 Esophago-Gastric Cancer. *Analytical Chemistry*, 85(12), 6121-6128, (2013).
- 553 29. Huang JZ, Kumar S, Abbassi-Ghadi N, Spanel P, Smith D, Hanna GB. Selected Ion Flow Tube
554 Mass Spectrometry Analysis of Volatile Metabolites in Urine Headspace for the Profiling of
555 Gastro-Esophageal Cancer. *Analytical Chemistry*, 85(6), 3409-3416, (2013).
- 556 30. Sethi S, Nanda R, Chakraborty T. Clinical Application of Volatile Organic Compound Analysis
557 for Detecting Infectious Diseases. *Clinical Microbiology Reviews*, 26(3), 462-475, (2013).
- 558 31. Purkhart R, Kohler H, Liebler-Tenorio E *et al.* Chronic intestinal Mycobacteria infection:
559 discrimination via VOC analysis in exhaled breath and headspace of feces using differential
560 ion mobility spectrometry. *Journal of Breath Research*, 5(2), 027103, (2011).
- 561 32. Sagar NM, Cree IA, Covington JA, Arasaradnam RP. The Interplay of the Gut Microbiome, Bile
562 Acids, and Volatile Organic Compounds. *Gastroenterology Research and Practice*, 398585,
563 (2015).
- 564 33. Phillips M, Basa-Dalay V, Blais J *et al.* Point-of-care breath test for biomarkers of active
565 pulmonary tuberculosis. *Tuberculosis*, 92(4), 314-320, (2012).
- 566 34. Filipiak W, Beer R, Sponring A *et al.* Breath analysis for in vivo detection of pathogens related
567 to ventilator-associated pneumonia in intensive care patients: a prospective pilot study.
568 *Journal of Breath Research*, 9(1), 016004, (2015).
- 569 35. Scarlata S, Pennazza G, Santonico M, Pedone C, Antonelli Incalzi R. Exhaled breath analysis
570 by electronic nose in respiratory diseases. *Expert Review of Molecular Diagnostics*, 15(7),
571 933-956, (2015).
- 572 36. Cauchi M, Fowler DP, Walton C *et al.* Application of gas chromatography mass spectrometry
573 (GC-MS) in conjunction with multivariate classification for the diagnosis of gastrointestinal
574 diseases. *Metabolomics*, 10(6), 1113-1120, (2014).
- 575 37. Walton C, Fowler DP, Turner C *et al.* Analysis of Volatile Organic Compounds of Bacterial
576 Origin in Chronic Gastrointestinal Diseases. *Inflammatory Bowel Diseases*, 19(10), 2069-
577 2078, (2013).
- 578 38. Probert CSJ, Reade S, Ahmed I. Fecal volatile organic compounds: a novel, cheaper method
579 of diagnosing inflammatory bowel disease? *Expert Review of Clinical Immunology*, 10(9),
580 1129-1131, (2014).

- 581 39. Probert CSJ. Role of faecal gas analysis for the diagnosis of IBD. *Biochemical Society*
582 *Transactions*, 39, 1079-1080, (2011).
- 583 40. Probert CSJ, Ahmed I, Khalid T, Johnson E, Smith S, Ratcliffe N. Volatile Organic Compounds
584 as Diagnostic Biomarkers in Gastrointestinal and Liver Diseases. *Journal of Gastrointestinal*
585 *and Liver Diseases*, 18(3), 337-343, (2009).
- 586 41. Markar SR, Wiggins T, Kumar S, Hanna GB. Exhaled Breath Analysis for the Diagnosis and
587 Assessment of Endoluminal Gastrointestinal Diseases. *Journal of Clinical Gastroenterology*,
588 49(1), 1-8, (2015).
- 589 42. Pleil JD, Stiegel MA, Risby TH. Clinical breath analysis: discriminating between human
590 endogenous compounds and exogenous (environmental) chemical confounders. *Journal of*
591 *Breath Research*, 7(1), 017107, (2013).
- 592 43. Costello BD, Amann A, Al-Kateb H *et al.* A review of the volatiles from the healthy human
593 body. *Journal of Breath Research*, 8(1), 014001, (2014).
- 594 44. Alonso M, Sanchez JM. Analytical challenges in breath analysis and its application to
595 exposure monitoring. *Trac-Trends in Analytical Chemistry*, 44, 78-89, (2013).
- 596 45. Lourenco C, Turner C. Breath analysis in disease diagnosis: methodological considerations
597 and applications. *Metabolites*, 4(2), 465-498, (2014).
- 598 46. Forbes SL, Rust L, Trebilcock K, Perrault KA, McGrath LT. Effect of age and storage conditions
599 on the volatile organic compound profile of blood. *Forensic Science Medicine and Pathology*,
600 10(4), 570-582, (2014).
- 601 47. Mochalski P, King J, Unterkofler K, Amann A. Stability of selected volatile breath constituents
602 in Tedlar, Kynar and Flexfilm sampling bags. *Analyst*, 138(5), 1405-1418, (2013).
- 603 48. Kim YH, Kim KH, Jo SH, Jeon EC, Sohn JR, Parker DB. Comparison of storage stability of
604 odorous VOCs in polyester aluminum and polyvinyl fluoride Tedlar (R) bags. *Analytica*
605 *Chimica Acta*, 712, 162-167, (2012).
- 606 49. Beauchamp J, Herbig J, Gutmann R, Hansel A. On the use of Tedlar (R) bags for breath-gas
607 sampling and analysis. *Journal of Breath Research*, 2(4), 046001, (2008).
- 608 50. Gilchrist FJ, Razavi C, Webb AK *et al.* An investigation of suitable bag materials for the
609 collection and storage of breath samples containing hydrogen cyanide. *Journal of Breath*
610 *Research*, 6(3), 036004, (2012).
- 611 51. Boeker P, Leppert J, Lammers PS. Comparison of Odorant Losses at the ppb-Level from
612 Sampling Bags of Nalophan (TM) and Tedlar (TM) and from Adsorption Tubes. In: *Nose2014:*
613 *4th International Conference on Environmental Odour Monitoring and Control*. DelRosso, R
614 (Ed. (2014) 157-162.
- 615 52. Mochalski P, Wzorek B, Sliwka I, Amann A. Suitability of different polymer bags for storage of
616 volatile sulphur compounds relevant to breath analysis. *Journal of Chromatography B-*
617 *Analytical Technologies in the Biomedical and Life Sciences*, 877(3), 189-196, (2009).
- 618 53. Pleil JD, Lindstrom AB. MEASUREMENT OF VOLATILE ORGANIC-COMPOUNDS IN EXHALED
619 BREATH AS COLLECTED IN EVACUATED ELECTROPOLISHED CANISTERS. *Journal of*
620 *Chromatography B-Biomedical Applications*, 665(2), 271-279, (1995).
- 621 54. Lindstrom AB, Pleil JD. A review of the USEPA's single breath canister (SBC) method for
622 exhaled volatile organic biomarkers. *Biomarkers*, 7(3), 189-208, (2002).
- 623 55. LeBouf RF, Stefaniak AB, Virji MA. Validation of evacuated canisters for sampling volatile
624 organic compounds in healthcare settings (vol 14, pg 977, 2012). *Environmental Science-*
625 *Processes & Impacts*, 16(8), 2048-2048, (2014).
- 626 56. Kramer R, Sauer-Heilborn A, Welte T, Guzman CA, Hofle MG, Abraham WR. A rapid method
627 for breath analysis in cystic fibrosis patients. *European Journal of Clinical Microbiology &*
628 *Infectious Diseases*, 34(4), 745-751, (2015).
- 629 57. Riter LS, Meurer EC, Cotte-Rodriguez I, Eberlin MN, Cooks RG. Solid phase micro-extraction
630 in a miniature ion trap mass spectrometer. *Analyst*, 128(9), 1119-1122, (2003).

- 631 58. Ma HY, Li X, Chen JM *et al.* Analysis of human breath samples of lung cancer patients and
632 healthy controls with solid-phase microextraction (SPME) and flow-modulated
633 comprehensive two-dimensional gas chromatography (GC x GC). *Analytical Methods*, 6(17),
634 6841-6849, (2014).
- 635 59. Tait E, Hill KA, Perry JD, Stanforth SP, Dean JR. Development of a novel method for detection
636 of *Clostridium difficile* using HS-SPME-GC-MS. *Journal of Applied Microbiology*, 116(4), 1010-
637 1019, (2014).
- 638 60. Tait E, Perry JD, Stanforth SP, Dean JR. Identification of Volatile Organic Compounds
639 Produced by Bacteria Using HS-SPME-GC-MS. *Journal of Chromatographic Science*, 52(4),
640 363-373, (2014).
- 641 61. Sanchez JM. Effects of packing density, flow and humidity on the performance of needle trap
642 devices. *Journal of Chromatography A*, 1369, 18-25, (2014).
- 643 62. Pfannkoch E, Whitecavage J. Analysis of volatiles in solid matrices: Comparison of the
644 sensitivities of static headspace GC, solid phase microextraction, and direct thermal
645 extraction. *Lc Gc North America*, 62-63, (2004).
- 646 63. Basanta M, Koimtzis T, Singh D, Wilson I, Thomas CLP. An adaptive breath sampler for use
647 with human subjects with an impaired respiratory function. *Analyst*, 132(2), 153-163, (2007).
- 648 64. Pennazza G, Santonico M, Incalzi RA *et al.* Measure chain for exhaled breath collection and
649 analysis: A novel approach suitable for frail respiratory patients. *Sensors and Actuators B-
650 Chemical*, 204, 578-587, (2014).
- 651 65. Pysanenko A, Spanel P, Smith D. Analysis of the isobaric compounds propanol, acetic acid
652 and methyl formate in humid air and breath by selected ion flow tube mass spectrometry,
653 SIFT-MS. *International Journal of Mass Spectrometry*, 285(1-2), 42-48, (2009).
- 654 66. Huang JZ, Kumar S, Boshier PR, Wakefield S, Cushnir JR, Hanna GB. Breath Analysis Using
655 SIFT-MS to Assess Metabolic Status in Patients After Gastro-oesophageal Cancer Surgery- a
656 Pilot Study. *Current Analytical Chemistry*, 9(4), 584-592, (2013).
- 657 67. Smith D, Spanel P. Direct, rapid quantitative analyses of BVOCs using SIFT-MS and PTR-MS
658 obviating sample collection. *Trac-Trends in Analytical Chemistry*, 30(7), 945-959, (2011).
- 659 68. Mashir A, Ti ART, Laskowski D *et al.* Exhaled Breath Analysis In Patients With Liver Cirrhosis
660 Using Soft Ion Flow Tube Mass Spectrometry(SIFT-MS). *American Journal of Respiratory and
661 Critical Care Medicine*, 183, (2011).
- 662 69. Turner C, Parekh B, Walton C, Spanel P, Smith D, Evans M. An exploratory comparative study
663 of volatile compounds in exhaled breath and emitted by skin using selected ion flow tube
664 mass spectrometry. *Rapid Communications in Mass Spectrometry*, 22(4), 526-532, (2008).
- 665 70. Smith D, Spanel P, Enderby B, Lenney W, Turner C, Davies SJ. Isoprene levels in the exhaled
666 breath of 200 healthy pupils within the age range 7-18 years studied using SIFT-MS. *Journal
667 of Breath Research*, 4(1), 017101, (2010).
- 668 71. Turner C, Spanel P, Smith D. A longitudinal study of ammonia, acetone and propanol in the
669 exhaled breath of 30 subjects using selected ion flow tube mass spectrometry, SIFT-MS.
670 *Physiological Measurement*, 27(4), 321-337, (2006).
- 671 72. Turner C, Spanel P, Smith D. A longitudinal study of breath isoprene in healthy volunteers
672 using selected ion flow tube mass spectrometry (SIFT-MS). *Physiological Measurement*,
673 27(1), 13-22, (2006).
- 674 73. Turner C, Spanel P, Smith D. A longitudinal study of ethanol and acetaldehyde in the exhaled
675 breath of healthy volunteers using selected-ion flow-tube mass spectrometry. *Rapid
676 Communications in Mass Spectrometry*, 20(1), 61-68, (2006).
- 677 74. Turner C, Spanel P, Smith D. A longitudinal study of methanol in the exhaled breath of 30
678 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS. *Physiological
679 Measurement*, 27(7), 637-648, (2006).
- 680 75. Boshier PR, Cushnir JR, Mistry V *et al.* On-line, real time monitoring of exhaled trace gases by
681 SIFT-MS in the perioperative setting: a feasibility study. *Analyst*, 136(16), 3233-3237, (2011).

76. Spanel P, Smith D. PROGRESS IN SIFT-MS: BREATH ANALYSIS AND OTHER APPLICATIONS. *Mass Spectrometry Reviews*, 30(2), 236-267, (2011).
77. Sovova K, Wiggins T, Markar SR, Hanna GB. Quantification of phenol in urine headspace using SIFT-MS and investigation of variability with respect to urinary concentration. *Analytical Methods*, 7(12), 5134-5141, (2015).
78. Pabary R, Huang J, Kumar S *et al.* SIFT-MS ANALYSIS OF EXHALED BREATH AS A NONINVASIVE DETERMINANT OF PSEUDOMONAS AERUGINOSA INFECTION IN CF PATIENTS. *Pediatric Pulmonology*, 48, 295-295, (2013).
79. Storer M, Dummer J, Sturney S, Epton M. Validating SIFT-MS Analysis of Volatiles in Breath. *Current Analytical Chemistry*, 9(4), 576-583, (2013).
80. Smith D, Turner C, Spanel P. Volatile metabolites in the exhaled breath of healthy volunteers: their levels and distributions. *Journal of Breath Research*, 1(1), 014004, (2007).
81. Kushch I, Schwarz K, Schwentner L *et al.* Compounds enhanced in a mass spectrometric profile of smokers' exhaled breath versus non-smokers as determined in a pilot study using PTR-MS. *Journal of Breath Research*, 2(2), 026002, (2008).
82. Schwarz K, Filipiak W, Amann A. Determining concentration patterns of volatile compounds in exhaled breath by PTR-MS. *Journal of Breath Research*, 3(2), 027002, (2009).
83. Boshier P, Priest O, Hanna G, Marczin N. Influence of Respiratory Manoeuvres on the On-Line Detection of Volatile Organic Compounds (VOCs) in Exhaled Breath by PTR-MS and SIFT-MS. *American Journal of Respiratory and Critical Care Medicine*, 179, (2009).
84. Moser B, Bodrogi F, Eibl G, Lechner M, Rieder J, Lirk P. Mass spectrometric profile of exhaled breath - field study by PTR-MS. *Respiratory Physiology & Neurobiology*, 145(2-3), 295-300, (2005).
85. Arendacka B, Schwarz K, Stolc S, Wimmer G, Witkovsky V. Variability issues in determining the concentration of isoprene in human breath by PTR-MS. *Journal of Breath Research*, 2(3), 037007, (2008).
86. Westenbrink E, Arasaradnam RP, O'Connell N *et al.* Development and application of a new electronic nose instrument for the detection of colorectal cancer. *Biosensors & Bioelectronics*, 67, 733-738, (2015).
87. Knobloch H, Schroedl W, Turner C, Chambers M, Reinhold P. Electronic nose responses and acute phase proteins correlate in blood using a bovine model of respiratory infection. *Sensors and Actuators B-Chemical*, 144(1), 81-87, (2010).
88. Joensen O, Paff T, Haarman EG *et al.* Exhaled Breath Analysis Using Electronic Nose in Cystic Fibrosis and Primary Ciliary Dyskinesia Patients with Chronic Pulmonary Infections. *Plos One*, 9(12), UNSP e115584, (2014).
89. Wlodzimierow KA, Abu-Hanna A, Schultz MJ *et al.* Exhaled breath analysis with electronic nose technology for detection of acute liver failure in rats. *Biosensors & Bioelectronics*, 53, 129-134, (2014).
90. Wang XR, Lizier JT, Berna AZ, Bravo FG, Trowell SC. Human breath-print identification by E-nose, using information-theoretic feature selection prior to classification. *Sensors and Actuators B-Chemical*, 217, 165-174, (2015).
91. Sibila O, Garcia-Bellmunt L, Giner J *et al.* Identification of airway bacterial colonization by an electronic nose in Chronic Obstructive Pulmonary Disease. *Respiratory Medicine*, 108(11), 1608-1614, (2014).
92. Asimakopoulos AD, Del Fabbro D, Miano R *et al.* Prostate cancer diagnosis through electronic nose in the urine headspace setting: a pilot study. *Prostate Cancer and Prostatic Diseases*, 17(2), 206-211, (2014).
93. Knobloch H, Turner C, Chambers M, Reinhold P. Serum Headspace Analysis With An Electronic Nose And Comparison With Clinical Signs Following Experimental Infection Of Cattle With Mannheimia Haemolytica. In: *Olfaction and Electronic Nose, Proceedings*. Pardo, M, Sberveglieri, G (Eds.) (2009) 439-442.

- 733 94. Smith D, Spanel P, Herbig J, Beauchamp J. Mass spectrometry for real-time quantitative
734 breath analysis. *Journal of Breath Research*, 8(2), 027101, (2014).
- 735 95. Bielecki Z, Stacewicz T, Wojtas J, Mikolajczyk J. Application of quantum cascade lasers to
736 trace gas detection. *Bulletin of the Polish Academy of Sciences-Technical Sciences*, 63(2), 515-
737 525, (2015).
- 738 96. Worle K, Seichter F, Wilk A *et al.* Breath Analysis with Broadly Tunable Quantum Cascade
739 Lasers. *Analytical Chemistry*, 85(5), 2697-2702, (2013).
- 740 97. Vaittinen O, Schmidt FM, Metsala M, Halonen L. Exhaled Breath Biomonitoring Using Laser
741 Spectroscopy. *Current Analytical Chemistry*, 9(3), 463-475, (2013).
- 742 98. Wojtas J, Bielecki Z, Stacewicz T, Mikolajczyk J, Nowakowski M. Ultrasensitive laser
743 spectroscopy for breath analysis. *Opto-Electronics Review*, 20(1), 26-39, (2012).
- 744 99. Wang CJ, Mbi A. A new acetone detection device using cavity ringdown spectroscopy at 266
745 nm: evaluation of the instrument performance using acetone sample solutions.
746 *Measurement Science & Technology*, 18(8), 2731-2741, (2007).
- 747 100. Liu Y, Gong Y, Wang C *et al.* Online breath analysis of propofol during anesthesia: clinical
748 application of membrane inlet-ion mobility spectrometry. *Acta Anaesthesiologica*
749 *Scandinavica*, 59(3), 319-328, (2015).
- 750 101. Jazan E, Mirzaei H. Direct analysis of human breath ammonia using corona discharge ion
751 mobility spectrometry. *Journal of Pharmaceutical and Biomedical Analysis*, 88, 315-320,
752 (2014).
- 753 102. Urbas AA, Harrington PB. Two-dimensional wavelet compression of ion mobility spectra.
754 *Analytica Chimica Acta*, 446(1-2), 393-412, (2001).
- 755 103. Knobloch H, Turner C, Spooner A, Chambers M. Methodological variation in headspace
756 analysis of liquid samples using electronic nose. *Sensors and Actuators B-Chemical*, 139(2),
757 353-360, (2009).
- 758 104. Smolinska A, Hauschild AC, Fijten RRR, Dallinga JW, Baumbach J, van Schooten FJ. Current
759 breathomics-a review on data pre-processing techniques and machine learning in
760 metabolomics breath analysis. *Journal of Breath Research*, 8(2), 027105, (2014).
- 761 105. Lorenzen PC, Walte HG, Bosse B. Development of a method for butter type differentiation by
762 electronic nose technology. *Sensors and Actuators B-Chemical*, 181, 690-693, (2013).
- 763 106. Zhang HX, Balaban MO, Principe JC. Improving pattern recognition of electronic nose data
764 with time-delay neural networks. *Sensors and Actuators B-Chemical*, 96(1-2), 385-389,
765 (2003).
- 766 107. Hirschfelder M, Forster A, Kuhne S *et al.* Using multivariate statistics to predict sensory
767 quality of marjoram from instrumental data. *Sensors and Actuators B-Chemical*, 69(3), 404-
768 409, (2000).
- 769 108. Weber CM, Cauchi M, Patel M *et al.* Evaluation of a gas sensor array and pattern recognition
770 for the identification of bladder cancer from urine headspace. *Analyst*, 136(2), 359-364,
771 (2011).
- 772 109. Wang T, Korposh S, Wong R, James S, Tatam R, Lee SW. A Novel Ammonia Gas Sensor Using
773 a Nanoassembled Polyelectrolyte Thin Film on Fiber-optic Long-period Gratings. *Chemistry*
774 *Letters*, 41(10), 1297-1299, (2012).
- 775 110. Wang T, Korposh S, James S, Tatam R, Lee SW, Ieee. *Polyelectrolyte Multilayer Nanoscale*
776 *Film Coated Long Period Grating Fiber Optic Sensors for Ammonia Gas Sensing* (2013).
- 777 111. Partridge M, Wong R, James SW, Davis F, Higson SPJ, Tatam RP. Long period grating based
778 toluene sensor for use with water contamination. *Sensors and Actuators B-Chemical*, 203,
779 621-625, (2014).
- 780 112. Kawano MS, Kamikawachi RC, Fabris JL, Muller M. Fiber optic sensor for methanol
781 quantification in biodiesel. *23rd International Conference on Optical Fibre Sensors*, 9157,
782 (2014).

783 113. Harnan SE, Tappenden P, Essat M *et al.* Measurement of exhaled nitric oxide concentration
784 in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and
785 NObreath. *Health Technology Assessment*, 19(82), 1-330, (2015).

786 114. Phillips M, Cataneo RN, Chaturvedi A *et al.* Detection of an Extended Human Volatome with
787 Comprehensive Two-Dimensional Gas Chromatography Time-of-Flight Mass Spectrometry.
788 *Plos One*, 8(9), e75274, (2013).

789 115. Amal H, Ding L, Liu BB *et al.* The scent fingerprint of hepatocarcinoma: in-vitro metastasis
790 prediction with volatile organic compounds (VOCs). *International Journal of Nanomedicine*,
791 7, 4135-4146, (2012).

792 116. Bos LDJ, Wang YY, Weda H *et al.* A simple breath sampling method in intubated and
793 mechanically ventilated critically ill patients. *Respiratory Physiology & Neurobiology*, 191, 67-
794 74, (2014).

795 117. Dixon E, Clubb C, Pittman S *et al.* Solid-Phase Microextraction and the Human Fecal VOC
796 Metabolome. *Plos One*, 6(4), e18471, (2011).

797 118. Filipiak W, Sponring A, Filipiak A *et al.* TD-GC-MS Analysis of Volatile Metabolites of Human
798 Lung Cancer and Normal Cells In vitro. *Cancer Epidemiology Biomarkers & Prevention*, 19(1),
799 182-195, (2010).

800 119. Turner C. VOC Analysis by SIFT-MS, GC-MS, and Electronic Nose for Diagnosing and
801 Monitoring Disease. *Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine*,
802 343-357, (2013).

803 120. Mansoor JK, Schelegle ES, Davis CE *et al.* Analysis of Volatile Compounds in Exhaled Breath
804 Condensate in Patients with Severe Pulmonary Arterial Hypertension. *Plos One*, 9(4),
805 e95331, (2014).

806 121. Ligor T, Ager C, Schwarz K, Zebrowski W, Amann A, Buszewski B. Comparison of Proton
807 Transfer Reaction-Mass Spectrometry and Gas Chromatography-Mass Spectrometry in
808 Analysis of Breath Samples. *Chemia Analityczna*, 54(3), 329-338, (2009).

809 122. Buszewski B, Ulanowska A, Kowalkowski T, Cieslinski K. Investigation of lung cancer
810 biomarkers by hyphenated separation techniques and chemometrics. *Clinical Chemistry and*
811 *Laboratory Medicine*, 50(3), 573-581, (2012).

812 123. Das MK, Bishwal SC, Das A *et al.* Investigation of Gender-Specific Exhaled Breath Volatome in
813 Humans by GCxGC-TOF-MS. *Analytical Chemistry*, 86(2), 1229-1237, (2014).

814 124. Phillips M, Cataneo RN, Greenberg J, Gunawardena R, Naidu A, Rahbari-Oskoui F. Effect of
815 age on the breath methylated alkane contour, a display of apparent new markers of
816 oxidative stress. *Journal of Laboratory and Clinical Medicine*, 136(3), 243-249, (2000).

817 125. Phillips M, Greenberg J, Awad J. METABOLIC, AND ENVIRONMENTAL ORIGINS OF VOLATILE
818 ORGANIC-COMPOUNDS IN BREATH. *Journal of Clinical Pathology*, 47(11), 1052-1053, (1994).

819 126. Phillips M. Method for the collection and assay of volatile organic compounds in breath.
820 *Analytical Biochemistry*, 247(2), 272-278, (1997).

821 127. Spanel P, Dryahina K, Smith D. A quantitative study of the influence of inhaled compounds
822 on their concentrations in exhaled breath. *Journal of Breath Research*, 7(1), 017106, (2013).

823 128. Schubert JK, Miekisch W, Birken T, Geiger K, Noldge-Schomburg GFE. Impact of inspired
824 substance concentrations on the results of breath analysis in mechanically ventilated
825 patients. *Biomarkers*, 10(2-3), 138-152, (2005).

826 129. Amann A, Miekisch W, Pleil J, Risby T, Schubert J. Methodological issues of sample collection
827 and analysis of exhaled breath. *Exhaled Biomarkers*, (49), 96-114, (2010).

828 130. Herbig J, Beauchamp J. Towards standardization in the analysis of breath gas volatiles.
829 *Journal of Breath Research*, 8(3), 037101, (2014).

830 131. Beauchamp JD, Pleil JD. Simply breath-taking? Developing a strategy for consistent breath
831 sampling. *Journal of Breath Research*, 7(4), 042001, (2013).

- 832 132. Bikov A, Paschalaki K, Logan-Sinclair R *et al.* Standardised exhaled breath collection for the
833 measurement of exhaled volatile organic compounds by proton transfer reaction mass
834 spectrometry. *Bmc Pulmonary Medicine*, 13, 43, (2013).
- 835 133. Wang TS, Pysanenko A, Dryahina K, Spanel P, Smith D. Analysis of breath, exhaled via the
836 mouth and nose, and the air in the oral cavity. *Journal of Breath Research*, 2(3), 037013,
837 (2008).
- 838 134. Spanel P, Turner C, Wang TS, Bloor R, Smith D. Generation of volatile compounds on mouth
839 exposure to urea and sucrose: implications for exhaled breath analysis. *Physiological*
840 *Measurement*, 27(2), N7-N17, (2006).
- 841 135. Smith D, Spanel P. Pitfalls in the analysis of volatile breath biomarkers: suggested solutions
842 and SIFT-MS quantification of single metabolites. *Journal of Breath Research*, 9(2), 022001,
843 (2015).
- 844 136. Pysanenko A, Spanel P, Smith D. A study of sulfur-containing compounds in mouth- and
845 nose-exhaled breath and in the oral cavity using selected ion flow tube mass spectrometry.
846 *Journal of Breath Research*, 2(4), 046004, (2008).
- 847 137. Smith D, Spanel P, Gilchrist FJ, Lenney W. Hydrogen cyanide, a volatile biomarker of
848 *Pseudomonas aeruginosa* infection. *Journal of Breath Research*, 7(4), 044001, (2013).
- 849 138. Shen CY, Wang HM, Huang CQ *et al.* On-line Detection of Volatile Sulfur Compounds in
850 Breath Gas by Proton Transfer Reaction Mass Spectrometry. *Chemical Journal of Chinese*
851 *Universities-Chinese*, 36(2), 236-240, (2015).
- 852 139. Reynolds JC, Jimoh MA, Guallar-Hoyas C, Creaser CS, Siddiqui S, Thomas CLP. Analysis of
853 human breath samples using a modified thermal desorption: gas chromatography
854 electrospray ionization interface. *Journal of Breath Research*, 8(3), 037105, (2014).
- 855 140. Basanta M, Ibrahim B, Douce D, Morris M, Woodcock A, Fowler SJ. Methodology validation,
856 intra-subject reproducibility and stability of exhaled volatile organic compounds. *Journal of*
857 *Breath Research*, 6(2), 026002, (2012).
- 858 141. Thekedar B, Oeh U, Szymczak W, Hoeschen C, Paretzke HG. Influences of mixed expiratory
859 sampling parameters on exhaled volatile organic compound concentrations. *Journal of*
860 *Breath Research*, 5(1), 016001, (2011).
- 861 142. Miekisch W, Hengstenberg A, Kischkel S, Beckmann U, Mieth M, Schubert JK. Construction
862 and Evaluation of a Versatile CO₂ Controlled Breath Collection Device. *Ieee Sensors Journal*,
863 10(1), 211-215, (2010).
- 864 143. Steeghs MML, Cristescu SM, Munnik P, Zanen P, Harren FJM. An off-line breath sampling and
865 analysis method suitable for large screening studies. *Physiological Measurement*, 28(5), 503-
866 514, (2007).
- 867 144. Bianchi F, Dommen J, Mathot S, Baltensperger U. On-line determination of ammonia at low
868 pptv mixing ratios in the CLOUD chamber. *Atmospheric Measurement Techniques*, 5(7),
869 1719-1725, (2012).